Proactive - Interviews for investors
Amplia COO discusses FAK inhibitor breakthrough in cancer trial - ASX SMIDcaps Conference
Dr. Rhiannon Jones of Amplia Therapeutics discussed the company's FAK inhibitors for fibrotic cancers, including pancreatic and ovarian cancer. The ACCENT trial showed complete responses in some patients, with tumours and metastases disappearing. Amplia is progressing trials and…